Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

GRIPBELL Receives U.S. Patent for Its New Hybrid Elite Performance Tool Sets; Revolutionary Fitness Product Line to be Released This Fall


GRIPBELL Revolutionary Fitness Product Line

“Everyone said a patent would be nearly impossible to harness, so we’re particularly thrilled to receive one,” said Ronald Obray, CEO of GRIPBELL.

The company also is awaiting approval of several other U.S. and international patents on its technology. It has filed with the Patent Cooperation Treaty (PCT) to protect the weight system in countries governed by the World Trade Organization and has filed a continuation patent application from its issued utility patent.

GRIPBELL’s handheld products are the most versatile, highest-quality fitness products ever built for gym or home use. They offer an all-in-one full-body workout and can replace many other handheld gym products, including dumbbells and kettle bells to simplify or intensify cross-training, physical therapy, weightlifting, yoga or interval training sessions.

GRIPBELL products were developed with every type of fitness level in mind. With its simple transportable design, a variety of weights and the potential to be incorporated into multiple types of training, GRIPBELL can enhance any individual fitness program.

“We believe we have built the most radically innovative fitness tools for all ages and fitness levels,” said Ronald Obray, GRIPBELL’s President and CEO. “Everyone said a patent would be nearly impossible to harness, so we’re particularly thrilled to receive one. The GRIPBELL weights are the ideal product to keep in shape at home — now more than ever.”

GRIPBELL’s fitness set is already proven in the marketplace. The company sold 25,000 units during the beta soft launch phase in 2017. Key features of the product include:


  • All-in-one product, consolidates all other handheld, weighted fitness equipment
  • Beautiful streamlined design
  • Color-coded weights from 3 to 90 pounds
  • Training for any age, fitness level or activity
  • Evenly distributed weight makes them easy to handle
  • Made with hypoallergenic materials
  • Easy to transport and lays flat in luggage for ultimate portability
  • Can be used as an isometric tool to build strength and gain more flexibility
  • Training exercise videos from experienced fitness instructors included

The newly issued utility patent is #10,449,404. It joins GRIPBELL’s three trademark registrations to protect the company’s intellectual property. A China patent for the product is pending with approval expected later this year.

“We will aggressively pursue our international patents over the next two years to find highly qualified distribution partners in the top 20 economic countries around the world,” Obray said.

About GRIPBELL

Based in Reno, Nevada, GRIPBELL develops, sells and distributes the revolutionary GRIPBELL products. In response to the increased demand for innovative, full-body, space-saving fitness equipment for all ages and fitness levels, the patent-pending GRIPBELL is a powerful all-in-one Elite Performance fitness tool that can be used at home, at the office, in commercial gyms, or even while traveling. For more information, go to gripbell.com.

SOCIAL MEDIA

Share article on social media or email:

A Conversation on Race & Food Allergy, featuring a panel of food Industry Experts


“For the Health™ is a webinar series creating a dialogue on racial and economic disparities in food allergy. It is my hope that words will move to action and we will see real lasting change.” Emily Brown, CEO

Food Equality Network (FEI), a nonprofit with the mission to improve health and end hunger in individuals diagnosed with food allergies and celiac disease announced the second of it’s “For the Health” webinar series, A Conversation on Race & Food Allergy.

The webinar will be moderated by Karen Palmer of Karen Palmer Coaching. She is a Certified Professional Coach, school operations consultant, and an advocate for food allergy families.

The expert panelists include industry leaders Susie Hultquist of Spokin Inc., Dan Waters of Enjoy Life Foods, Louis & Joanne Giorgi of Natalie Giorgi Sunshine Foundation & Dr. Ruchi Gupta of Northwestern Medicine Center for Food Allergy & Asthma Research (CFAAR).

This free webinar is FRIDAY, JULY 17, 2020 at 11:00 am EST/10:00am CST. Register to attend at “The For the Health™

The “The For the Health™ webinar series was inspired by this Open Letter to the Food Allergy Community written by Emily Brown, CEO of Food Equality Initative, after the murder of George Floyd that has focused the nation’s attention on the public health crisis of police brutality, which targets black men and women.

Emily Brown says this, “The For the Health™ webinar series is creating a dialogue on racial and economic disparities in food allergy. It is my hope that words will move to action and we will see real lasting change.”

Research shows that Black children are 7% more likely to have food allergies compared to white children, are diagnosed less frequently, receive less medical care, and are more likely to experience anaphylaxis.

This For The Health™ webinar is sponsored by Enjoy Life Foods, Natalie Giorgi Sunshine Foundation, the Northwestern University Center For Allergy and Asthma Research and Spokin.

Share article on social media or email:

The Society to Improve Diagnosis in Medicine Receives $129,000 PCORI Award for Multi-Stakeholder Effort to Issue Research Recommendations


“To navigate this new era of “telediagnosis,” research needs to identify the best methods for providing a diagnosis virtually and strategies for patients and clinicians to make effective use of the technology,” said Suzanne Schrandt, Senior Patient Engagement Advisor at SIDM.

The Society to Improve Diagnosis in Medicine (SIDM) has been approved for a $129,612 Eugene Washington PCORI Engagement Award from the Patient-Centered Outcomes Research Institute (PCORI). The award, part of the PCORI Special Cycle: Supporting Engagement in and Dissemination of PCOR/CER in the Context of COVID-19 funding, will address research needs around the growing field of virtual visits and telediagnosis. The project will convene a multi-stakeholder group to examine and issue recommendations on the most important research questions regarding diagnostic quality and telediagnosis in the wake of COVID-19.

“The COVID-19 pandemic has transformed the usage of telemedicine overnight, establishing it as a mainstay for healthcare delivery and diagnosis. To navigate this new era of “telediagnosis” research needs to identify the best methods for providing a diagnosis virtually and strategies for patients and clinicians to make effective use of the technology,” said Suzanne Schrandt, Senior Patient Engagement Advisor at SIDM. “Previous research has documented that some uses of telemedicine actually aid in the diagnostic process and mitigate risk of some errors, but it remains to be seen whether broader use of TeleDx will lead to new types of diagnostic errors, reproduce similar errors to those seen in in-person care settings, or perhaps even improve diagnostic accuracy.”

Convened by SIDM, “Learning While We Build: Identifying the Must-Know Research Questions for Safe and Effective Telediagnosis” will bring together a multi-stakeholder group including SIDM’s Patient Engagement Committee, WomenHeart, Sepsis Alliance, The American Telemedicine Association, Advocate Aurora Health, The Council for Medical Specialty Societies, The Digital Medicine Society, Teladoc Health and others to make recommendations on the research most needed by the field. Through an environmental scan of available literature, and a series of virtual listening sessions, the project will identify the TeleDX questions in most critical need of study. Listening session participants will share their insights and ideas about ensuring all interested stakeholders – clinicians, community-based practices, hospitals and health systems, virtual health companies, and patients and caregivers — can most effectively be mobilized and prepared for this important work.

“The rapid and unprecedented adoption of telemedicine, and the more recent recognition that telediagnosis has unique attributes that must be considered within the broader domain of telemedicine, provides us a rare opportunity to learn, in real time, where the biggest gaps in knowledge and practice are”, said Paul Epner, CEO and co-founder of SIDM. “We know diagnostic errors are the most common, catastrophic and costly of medical errors. Now we need to identify where further research could lead to TeleDx as an improvement strategy for diagnostic excellence.”

The “Learning While we Build” project is part of a portfolio of projects that PCORI has funded to help develop a community of patients and other stakeholders equipped to participate as partners in comparative clinical effectiveness research (CER) and disseminate PCORI-funded study results. Through the Engagement Award Program, PCORI is creating an expansive network of individuals, communities and organizations interested in and able to participate in, share, and use patient-centered CER.

According to Jean Slutsky, PCORI’s Chief Engagement and Dissemination Officer, “This project was selected for Engagement Award funding because it will help their community increase their capacity to participate across all phases of the PCOR/CER process while responding to contextual changes as a result of the COVID-19 pandemic. We look forward to working with SIDM throughout the course of their year-long project.”

SIDM’s project and the other projects approved for funding by the PCORI Engagement Award Program were selected through a highly competitive review process in which applications were assessed for their ability to meet PCORI’s engagement goals and objectives, as well as program criteria. For more information about PCORI’s funding to support engagement efforts, visit http://www.pcori.org/content/eugene-washington-pcori-engagement-awards/.

PCORI is an independent, non-profit organization authorized by Congress in 2010 to fund comparative effectiveness research that will provide patients, their caregivers, and clinicians with the evidence needed to make better-informed health and healthcare decisions. PCORI is committed to seeking input from a broad range of stakeholders to guide its work.

###

About the Society to Improve Diagnosis in Medicine (SIDM)

The Society to Improve Diagnosis in Medicine (SIDM) catalyzes and leads change to improve diagnosis and eliminate harm from diagnostic error. We work in partnership with patients, their families, the healthcare community and every interested stakeholder. SIDM is the only organization focused solely on the problem of diagnostic error and improving the accuracy and timeliness of diagnosis. In 2015, SIDM established the Coalition to Improve Diagnosis, to increase awareness and actions that improve diagnosis. Members of the Coalition represent hundreds of thousands of healthcare providers and patients—and the leading health organizations and government agencies involved in patient care. Together, we work to find solutions that enhance diagnostic safety and quality, reduce harm, and ultimately, ensure better health outcomes for patients. Visit http://www.improvediagnosis.org to learn more. Follow us on Twitter and Facebook.

Share article on social media or email:



Acara Partners and PatientNOW Release Key Sales Metrics After COVID-19 Shutdown


Francis X. Acunzo, CEO of Acara Partners and chair of the board of directors for the Aesthetic Business Institute.

With many people spending hours each day in Zoom meetings over the last two to three months, everyone has been looking at themselves on the screen non-stop. This has had an impact on the increase in demand for aesthetic procedures.

Acara Partners and PatientNOW announced that aesthetic medical practices are seeing very positive sales results nationwide after reopening following the COVID-19 shutdown.

These findings were presented during a recent webinar hosted by the Aesthetic Business Institute and are based on an analysis of PatientNOW’s dataset involving 378 aesthetic medical practices including plastic surgeons, dermatologists, and medical spas throughout the United States. The 378 practices included in the data analysis are those that were open in June of 2019 and 2020, and are a subset of the 900+ practices in the PatientNOW database.

“This is a large sampling of data in the aesthetic medical industry, involving over 661,000 patients, spread out over the entire United States,” said Wes Olis, director of products at PatientNOW. “This includes about 65% core practices (dermatologists and plastic surgeons) and 35% non-core (medspas, etc.).”

When comparing June 2019 to June 2020 overall, core practice sales are up 8.8%, and non-core sales increased 18.8%. However, based on a set of specific procedures (injectables, non-invasive body contouring, laser skin rejuvenation, clinical skin care, and retail products) the core increase is 22.4% and the non-core is up 58.5%.

“Part of these increases are attributable to a pent-up demand for aesthetic services,” commented Francis X. Acunzo, CEO of Acara Partners and chair of the board of directors for the Aesthetic Business Institute. “But we also believe there is a marketplace expansion of aesthetic services taking place.”

Why the growth in aesthetic medical sales in June 2020 as most practices reopen after the COVID-19 shutdown? Acunzo believes there are four factors at play:


  • Pent-up consumer demand from aesthetic practices being closed for over two months
  • The “Zoom Effect.” With many people spending hours each day in Zoom meetings over the last two to three months, everyone has been looking at themselves on the screen non-stop. This has had an impact on the increase in demand for aesthetic procedures.
  • For the past two years, consumers have not been able to keep up with new aesthetic technology available to them. The shutdown over the last two to three months has enabled people to research this new technology and procedures, leading to an increase in demand.
  • Aesthetic practices with the largest sales increases kept up or increased their marketing spends during the shutdown and through their reopening.

“We have practices in different regions of the country posting amazing sales results,” Acunzo added. “For example, one practice in the southwest completed $550,000 in sales during a one-day virtual event. Another practice in the northeast reported sales were up 50% this June compared to last year.”

Some of the strongest sales numbers involve injectables, where non-core practices are seeing a 61% increase and core practices 33%. Overall, surgical procedures are up 8.4%, with some plastic surgeons seeing 50-100% increases from last June.

What does the immediate future hold for the aesthetic medical industry? Acunzo cautions that there are three external factors that will impact sales moving forward.

“Certainly, another shutdown due to a spike in COVID-19 cases will obviously impact sales for aesthetic practices,” Acunzo added. “In the same way, the availability of a COVID-19 vaccine and/or a treatment will have an enormous effect on our industry.”

Acara Partners and PatientNOW plan to produce quarterly reports moving forward to analyze aesthetic practices during this time of uncertainty.

To view the full webinar, please visit aestheticbusinessinstitute.com/video-resources.

PatientNOW was founded in 2004, providing an all-in-one mobile, tablet, and Windows app that enables clinicians to manage their entire practice from a single piece of software, eliminating the need to use four to five separate programs for cash-pay medical practices. More details at patientnow.com.

Acara Partners was founded in 2003 by entrepreneurial husband-and-wife team Francis and Colleen Acunzo. They have applied their years of experience in the aesthetic medical world to establish Acara Partners as the industry’s quintessential, comprehensive business advisory, marketing, advertising, and digital agency. More details at acarpartners.com.

The Aesthetic Business Institute (ABI) was established in 2017 and launched an online educational platform in 2019, providing the leading industry intelligence for the aesthetic medical industry. ABI is part of the Acara Partners family of businesses. More details found at aestheticbusinessinstitute.com.

Share article on social media or email:

Leveraging a Modular Approach, Upcoming Webinar Hosted by Xtalks


Xtalks Life Science Webinars

Through an industry case study, the presenters will discuss the importance of choosing a vendor who offers a configurable, fully featured solution that can be rapidly implemented.

The procurement and implementation of eClinical software systems can be a difficult undertaking for many organizations associated with clinical trials. While the utilization of these systems is necessary to allow clinical operations teams to operate with high efficiency, it can be a significant drain on productivity during the implementation phase. In many cases, the team tasked with working with the software vendor to configure and deploy the systems is already fully utilized in their “day jobs,” and software implementation is a task placed on top of an already full list.

Through an industry case study, the presenters will discuss the importance of choosing a vendor who offers a configurable, fully featured solution that can be rapidly implemented.

Join Justin Hunt, Director, Technology Product Management, Bioclinica and Michelle Butler, CEO and President, Veraxia in a live webinar on Thursday, August 6, 2020 at 11am EDT (4pm BST/UK).

For more information or to register for this event, visit Rapid CTMS Implementation: Leveraging a Modular Approach.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Miles Announces Growth Milestones


We are thrilled to support Miles’ mission to deliver value for every mile traveled and enhance the experience across every mode of transportation. -Nadim Matuk, Liil Ventures, Investment Principal

Miles, the world’s first loyalty program that rewards daily movement, has experienced notable momentum in 2020 as it continues to scale and grow. The team is excited to announce a strategic investment from Liil Ventures and the surpassing of 500,000 reward redemptions for brand partners on the platform. Miles also added 50 new reward partners in just the last two months.

Liil Ventures is the corporate venture capital arm of Mobility ADO – one of the largest global passenger mobility companies in the world that serves 650M passengers annually and has a presence in Latin America and Europe – and focuses on growth opportunities in smart cities, urban tech, and new mobility. Their mission to maintain and improve the quality of living in densely populated urban settings aligns well with the value that Miles has to offer. Liil Ventures’ investment will support the Miles’ program as they expand their services across the world.

“We are thrilled to support Miles’ mission to deliver value for every mile traveled and enhance the experience across every mode of transportation. We are looking forward to helping Miles’ promising team to expand their services abroad, generating the right incentives in multiple locations. We believe that rewarding a universal behavior can generate a sustainable & positive impact on the livelihood of hundreds of millions.” – Nadim Matuk, Liil Ventures, Investment Principal

Miles’ mission is to deliver value for every mile traveled, while rewarding greener forms of travel even further. With Miles’ ability to reward all modes of travel and transportation, users of the app earn reward points as “miles” from their daily travel and commute activities and then use those “miles” to redeem exclusive rewards, participate in raffles and challenges, or donate to a good cause.

“We’re excited to have found an amazing strategic investor that believes and fits so well with the Miles vision and mission. With Liil Ventures’ support, we look forward to bringing Miles’ solution to the EU and Latin American markets.” – Jigar Shah, Miles, CEO and Co-founder

Miles also partners with cities and transit authorities to provide value across their entire business model. By leveraging predictive AI and analytics available through the Miles platform, cities can better understand traffic patterns and trends by mode of transportation, and in turn, introduce targeted rewards to increase ridership. Miles’ newest city partner, Jacksonville Transportation Authority, will look to incentivize the Jacksonville community to more frequently utilize public transit and services like their First Coast Flyer by rewarding loyal riders. Miles’ program already has proven results with other city transportation agencies in invoking mode shift behavior.

Partnering with over 200 brands

With the continuation of bringing more and more popular brands to the platform, the Miles community can discover new and exciting rewards each week. Despite recent economic challenges, Miles added 50 new reward partners in just the last two months. Those new partner offerings, combined with enhanced reward discoverability and personalization on the platform, has prompted the Miles community to redeem over 500,000 rewards with and for our brand partners. These rewards provide special offers on products and services from great brands like Garmin, Chewy, Pandora, DoorDash, HP, and more and have saved Miles members over $10 million. We can expect more new and exciting rewards to be available on the Miles platform as it continues to grow.

Pivoting during COVID-19

Miles is always committed to the health and safety of its community. Through these difficult months, Miles adjusted its motto and mission from “Travel, Rewarded” to “Staying Home, Rewarded” and “Social Distancing, Rewarded”. To support users and brands during this time of limited travel, Miles has been periodically offering promo codes of 500 bonus miles for remaining at home. Miles also currently awards 20X the bonus miles for safer travel options such as walking, running, and biking.

Miles created a unique “Staying Home” rewards category featuring options to help stay safe, stay fit, and stay entertained. The rewards include meal and pet food delivery, in-home exercise, cleaning products, streaming services, among others, and are priced at only 50 miles each to make them affordable for all Miles users. Miles users can also donate their “miles” to nonprofit organizations and over the past few months, donations from the Miles community led to 20,000 meals provided through Feeding America and $10,000 worth of supplies fighting COVID-19 facilitated through Good360.

—

Miles is the first universal rewards app that delivers value for every mile of commute & travel across every mode of transportation – with greener forms of travel rewarded even further. Using the miles you earn, enjoy redeeming rewards that range from free products and services to credits and savings on over 200 top brands such as Garmin, Chewy, Postmates, and more.

Miles is backed by strategic investors from JetBlue Technology Ventures, Scrum Ventures, Porsche Digital, Liil Ventures, Urban Us, Sony Innovation Fund, Panasonic, and SAIC.

The Miles app is available to download on iOS and Android.

Share article on social media or email:

Mount Sinai Researchers Identify Distinct Subtypes of Polycystic Ovary Syndrome With Novel Genetic Associations


Mount Sinai researchers have for the first time identified reproductive and metabolic subtypes of polycystic ovary syndrome (PCOS) that are associated with novel gene regions. The findings, which used clustering of clinical, metabolic, and hormonal data from women with the syndrome, promise to transform understanding of the cause of PCOS and, accordingly, will have far-reaching implications for its diagnosis and treatment. The results were published in PLOS Medicine on Tuesday, June 23.

PCOS is among the most common endocrine conditions in reproductive-age women, affecting up to 15 percent of this population worldwide. It is a leading cause of infertility and type 2 diabetes in young women. The cause of PCOS is unknown, but there is a strong inherited susceptibility to the disorder. It is currently diagnosed using different sets of clinical criteria based on expert opinion. There is considerable controversy about which criteria are the most appropriate.

“We’re starting to make headway on what causes PCOS. It’s very frustrating for patients because it’s poorly understood and patients often see several physicians before PCOS is diagnosed,” said senior author Andrea Dunaif, MD, Chief of the Hilda and J. Lester Gabrilove Division of Endocrinology, Diabetes and Bone Disease at the Mount Sinai Health System. “Through genetics, we’re beginning to understand the condition and may have specific targeted therapies in the not-too-distant future.”

Using clinical, biochemical, and genotype data from their previously published PCOS genome-wide association study (GWAS), Dr. Dunaif and her team identified the subtypes using cluster analysis, a way of aggregating similar data in an unbiased manner. Unsupervised cluster analysis, meaning there are no predetermined models of data, was performed in the GWAS cohort of 893 PCOS cases. The clusters were then replicated in an independent group of 263 PCOS cases.

The clustering revealed two distinct PCOS subtypes: a “reproductive” group characterized by higher luteinizing hormone (LH), a hormone that triggers ovulation and acts on the ovaries, and higher levels of sex hormone binding globulin (SHBG), a protein that regulates the ability of testosterone to enter its target tissues, with relatively low body mass index (BMI) and insulin levels; and a “metabolic” group characterized by higher BMI, glucose, and insulin levels with lower SHBG and LH levels.

This current paper builds upon a study that Dr. Dunaif and her team published in The Journal of Endocrinology and Metabolism in April 2019 where they found, using family-based genetic analysis, that rare genetic variants in a gene involved in male hormone production, DENND1A, play major roles in the development of PCOS. This genetic variation could serve as a marker for early PCOS detection.

In the study published today, the researchers developed a predictive model and classified the reproductive and metabolic subtypes in a family-based cohort of 73 women with PCOS, including their sisters. They found that the subtypes tended to cluster in families. They also found that carriers of the previously reported rare variants in DENND1A were more likely to have the reproductive subtype of PCOS. The results suggest that these subtypes are biologically relevant since they have distinct genetic architectures. The findings will substantially assist in gene discovery by allowing the selection of more homogeneous PCOS subtypes, which could increase the likelihood of identifying disease-associated genes.

“In contrast to classifying disorders based on expert opinion, this is a very powerful objective approach to categorizing syndromes like PCOS into distinct subtypes with different causes, treatment and clinical outcomes,” said Dr. Dunaif.

The study was supported by grants from the National Institutes of Health.

Share article on social media or email:

AltMed Enterprises Secures Valuable U.S. and European Patents for its Medical Cannabis Encapsulation Technology and Trademark on EnCaps™


News Image

This formulation innovation simply delivers more effective and faster-acting effects that will continue to clearly differentiate the MÜV Products line from others

Alternative Medical Enterprises, LLC has been awarded patents for the United States and European Union for its Medical Cannabis Encapsulation Technology and Trademark on EnCaps™. EnCaps Products are an expanding product line at the 23 MÜV™ Medical Cannabis Dispensaries in Florida and at the flagship Arizona dispensary in Phoenix.

“Patents are extremely difficult to earn in the cannabis industry,” said Mike Smullen, Chariman and CEO of AltMed Entreprises. “These patents validate our ongoing investment in research and development while also establishing intellectual properties that can be protected. It also further bolsters our award winning MÜV Medical Cannabis brand which has become synonymous with quality and consistency.”

MÜV EnCaps technology is available in a growing number of MÜV products and formulations including MÜV Transdermal Patches (THC, CBD and 1:1 ratio), Tinctures (THC, CBD and 1:1), Transdermal gels (THC, CBD and 1:1) as well as Capsules (THC, CBD and 1:1). The same patented formulation is also part of the newly launched MÜV Health over the counter hemp-derived CBD product line cbdbymuv.com.

EnCaps products are for patients who prioritize a smoke-free delivery method that is both long-lasting and fast-acting. The MÜV EnCaps process makes cannabinoids water-soluble and therefore more readily absorbed within the body. This dramatically improves both onset time and overall bioavailability, creating a more effective product.

Brief Summary of the patent protected and trademarked EnCaps™ technology:

  • The term encapsulation refers to a small sphere which contains THC, CBD, and terpenes that are enveloped within the interior
  • Creates better absorption of transdermal and tincture formulations
  • Provides faster and long-lasting relief for patients

“These techniques have been widely used in the pharmaceutical industry to improve the efficiency and efficacy of products,” said Todd Beckwith, AltMed Director of Corporate Affairs. “This formulation innovation simply delivers more effective and faster-acting effects that will continue to clearly differentiate the MÜV Products line from others.”

About AltMed Enterprises – Alternative Medical Enterprises, LLC, headquartered in Sarasota, FL and doing business as AltMed Enterprises, is a fully integrated medical cannabis company that brings compassion, community engagement and pharmaceutical industry precision to the development, production and dispensing of medical cannabinoids.

About MÜV™ – The MÜV brand of cannabis infused products was launched in Arizona in 2016 and quickly gained international attention and recognition. In its first six months alone, MÜV received four best of Arizona medical cannabis awards, including two first prizes for its proprietary Ethanol extractions that are the basis of all MÜV products.

Forward-Looking Statements – To the extent any statements made in this press release contain information that is not historical, these statements are forward-looking in nature and merely express our beliefs, expectations or opinions. For example, words such as “may,” “should,” “estimates,” “predicts,” “continues,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” “strategy” and similar expressions are intended to identify forward-looking statements. Such statements are based on current expectations or estimates and involve a number of known and unknown risks and uncertainties that could cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause or contribute to these differences include, but are not limited to, the following: (i) our ability to implement our business strategy of distributing high quality cannabis products where permissible under applicable law; (ii) availability and cost of additional capital; (iii) our ability to attract, retain and motivate qualified employees and management; (iv) the impact of federal, state or local government regulations; (v) competition in the cannabis industry; (vi) our ability to generate revenues; and (vii) litigation in connection with our business. All forward-looking statements included in this press release and attributable to us or any person acting on our behalf are qualified by this cautionary statement. Forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.

Share article on social media or email:

Nellson, LLC Recognizes Three Key Executives


I am pleased to recognize Bart Child, Ray Collins and Marty Hudak-Roos for their extraordinary contributions to Nellson’s ongoing success. Their new titles better reflect their critical roles during our aggressive transformation over the last several years under the ownership of Kohlberg & Company.

Nellson, LLC (Nellson), a leading North American manufacturer of branded and private label nutritional bar and functional powder solutions, recently announced that Bart Child has been named Chief Commercial Officer, Ray Collins has been named Chief Human Resource Officer, and Martha (Marty) Hudak-Roos has been named Nellson’s Chief Quality Officer.

“I am pleased to recognize Bart Child, Ray Collins and Marty Hudak-Roos for their extraordinary contributions to Nellson’s ongoing success,” said Jamie Better, Chief Executive Officer of Nellson. “Their new titles better reflect their critical roles during our aggressive transformation over the last several years under the ownership of Kohlberg & Company. With the acquisitions of Multibar, Genysis Brand Solutions, and the bar and powder operations of Nature’s Bounty, Nellson has tripled in size. We’ve also built a state-of-the-art bar facility in Ontario, California greatly expanding our growth capacity and capabilities.”

Better continued, “Throughout all the challenges and successes of this transformation, Nellson and our brand partners have benefitted from the talent, leadership and tireless effort of individuals such as Bart Child, Ray Collins and Marty Hudak-Roos. These outstanding executives have been my partners in leading Nellson during this extraordinary time in our company’s history and I thank them for all they do.”


  • Bart Child has been named Nellson’s Chief Commercial Officer (CCO) and oversees all activities related to revenue generation including Research and Development. In this capacity, he maintains close ties with all key brand partners and is responsible for streamlining Nellson’s product development processes. Mr. Child has been with Nellson since 2007 and his deep industry experience, knowledge and judgement are invaluable.
  • Ray Collins has been designated Nellson’s Chief Human Resource Officer (CHRO). In this capacity, he oversees all Human Resources activity, including Safety. Mr. Collins joined Nellson in 2015 and has been responsible for upgrading all Human Resources policies and systems. He has been the driving force behind Nellson’s recent initiatives to improve communication, transparency and employee safety. During the last few months, Mr. Collins has led Nellson’s response to the Coronavirus pandemic.
  • Martha (Marty) Hudak-Roos has been named Nellson’s Chief Quality Officer (CQO). In this capacity, she oversees all activities related to product quality, food safety and regulatory compliance. Ms. Hudak-Roos was Nellson’s Director of Quality at multiple facilities before leaving to take on the lead quality-control role at a pet food manufacturer. Since rejoining Nellson in 2017, she has upgraded Nellson’s quality and regulatory processes while steadily driving down the cost of quality.

Visit http://www.nellsonllc.com to find out more about Nellson’s latest nutrition powder and bar solutions.

About Nellson

Nellson, the leading full-service nutritional bar and powder provider in North America, is based in Anaheim, California with production locations in California, Utah, and Quebec. Founded in 1962, Nellson has over 55 years of diversified expertise in nutrition platforms for bars and powders, serving the sports performance, health and wellness, weight management, and medical nutrition market segments. Nellson offers formulation expertise, quality assurance, regulatory support, flexible production, and sales and marketing support.

About Kohlberg & Company

Kohlberg & Company is a leading private equity firm specializing in middle market investing. Since its inception in 1987, Kohlberg has organized nine private equity funds, through which it has raised over $10 billion of committed equity capital. Over its 33-year history, Kohlberg has completed 80 platform investments and nearly 200 add-on acquisitions, with an aggregate transaction value of over $22 billion. For more information, visit http://www.kohlberg.com.

Share article on social media or email:

Capio and Attunely announce new partnership to help patients achieve financial wellness


Today, Capio announced a new strategic partnership with Seattle-based Attunely to further support its ongoing commitment to expand consumer offerings and enhance the overall patient experience.

Under this new partnership, the companies will actively collaborate to leverage Attunely’s machine learning capabilities to better understand consumer needs and increase successful outcomes. In addition, both organizations believe the partnership will provide ongoing opportunities to identify and improve business efficiencies that better serve Capio’s provider clients.

“The global pandemic is changing the way healthcare is managed and delivered to patients. These unprecedented challenges, combined with the resulting economic impacts, have negatively impacted many of our consumers. Capio maintains our relentless commitment to providing the individual attention and offerings needed to successfully resolve outstanding healthcare accounts. We believe that Attunely and their leading machine learning technology, coordinated with the efforts of our internal teams, will be instrumental to achieving these successes,” said Mark Detrick, co-founder and CEO of Capio.

“Attunely has deep experience building powerful optimization technologies tailored to our customers’ consumer strategies,” notes Scott Ferris, founder and CEO of Attunely. “Capio has been the leading purchaser of healthcare receivables for the past decade, and we are thrilled to partner with them on this important initiative.”

About Capio

Capio assists healthcare providers and physician organizations increase cash flow, while also lowering their bad debt expense. To date, Capio has acquired and provided consumer services to over $35B in patient accounts receivable via partnerships with more than 525 provider clients across the United States. To learn more about Capio, please visit http://www.capiopfw.com.

About Attunely Inc.

Attunely is a proven, compliant, and trustworthy machine learning platform that makes the recovery of receivables easy, seamless, and profitable. To learn more about Attunely, please visit http://www.attunely.com.

Share article on social media or email: